Trial Outcomes & Findings for Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program) (NCT NCT00590005)

NCT ID: NCT00590005

Last Updated: 2014-02-10

Results Overview

Exhaled nitric oxide concentrations as measured by collection of exhaled breath into a mylar bag

Recruitment status

COMPLETED

Target enrollment

225 participants

Primary outcome timeframe

baseline and after 21 days

Results posted on

2014-02-10

Participant Flow

Children were recruited from January 2003 to June 2011 from the Emory Children's Center asthma clinic.

Children with physician diagnosed asthma were enrolled and underwent comprehensive phenotypic characterization consisting of pulmonary function measures, biomarker assessment, and allergy assessment.

Participant milestones

Participant milestones
Measure
Children With Severe Asthma
This group includes children with severe asthma diagnosed according to American Thoracic Society criteria (2000 workshop definition)
Children With Non-severe Asthma
This group includes child with physician-diagnosed asthma who did not meet criteria for severe asthma.
Overall Study
STARTED
106
119
Overall Study
COMPLETED
106
119
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Children With Asthma
n=225 Participants
The cohort consists of children with physician-diagnosed asthma across a wide range of severity (mild, moderate, severe)
Age, Categorical
<=18 years
225 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
Age, Continuous
11.8 years
STANDARD_DEVIATION 3.6 • n=99 Participants
Sex: Female, Male
Female
102 Participants
n=99 Participants
Sex: Female, Male
Male
123 Participants
n=99 Participants
Region of Enrollment
United States
225 participants
n=99 Participants

PRIMARY outcome

Timeframe: baseline and after 21 days

Population: 225 children were enrolled into the study and completed baseline assessments. Only 40 children were followed longitudinally. The results from only those 40 children are shown here.

Exhaled nitric oxide concentrations as measured by collection of exhaled breath into a mylar bag

Outcome measures

Outcome measures
Measure
Children With Severe Asthma
n=20 Participants
This group includes children with severe asthma diagnosed according to American Thoracic Society criteria (2000 workshop definition)
Children With Non-severe Asthma
n=20 Participants
This group includes child with physician-diagnosed asthma who did not meet criteria for severe asthma.
Exhaled Nitric Oxide at Baseline and Over the Observational Period
Exhaled nitric oxide value at 21 days
15.1 parts per billion
Standard Deviation 5.4
9.9 parts per billion
Standard Deviation 5.8
Exhaled Nitric Oxide at Baseline and Over the Observational Period
Exhaled nitric oxide baseline value
13.7 parts per billion
Standard Deviation 7.4
8.6 parts per billion
Standard Deviation 6.2

SECONDARY outcome

Timeframe: baseline and 21 days

Population: 225 children with asthma were enrolled in the study and completed baseline assessments. Only 40 children were followed longitudinally. The data from those 40 children are shown here.

Breath condensate pH was measured by the RTube (trademark) device. This device is a plastic tube with a one-way exhalation valve and a chilled aluminum sleeve. pH (the log of hydrogen ion concentration) was measured using an Orion pH meter and probe calibrated in 4.0, 7.0, and 10.0 pH solutions.

Outcome measures

Outcome measures
Measure
Children With Severe Asthma
n=20 Participants
This group includes children with severe asthma diagnosed according to American Thoracic Society criteria (2000 workshop definition)
Children With Non-severe Asthma
n=20 Participants
This group includes child with physician-diagnosed asthma who did not meet criteria for severe asthma.
Reduction in Breath pH
Breath pH at 21 days
7.08 log of hydrogen ion concentration (pH)
Standard Deviation 0.52
7.58 log of hydrogen ion concentration (pH)
Standard Deviation 0.32
Reduction in Breath pH
Breath pH at baseline
7.68 log of hydrogen ion concentration (pH)
Standard Deviation 0.69
7.63 log of hydrogen ion concentration (pH)
Standard Deviation 0.88

Adverse Events

Children With Severe Asthma

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Children With Non-severe Asthma

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Anne Fitzpatrick, Director, Emory Asthma Clinical Research Program

Emory University Department of Pediatrics

Phone: 404-727-9112

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place